GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Receivables
中文

Verici Dx (Verici Dx) Total Receivables

: $0.14 Mil (As of Jun. 2023)
View and export this data going back to 2021. Start your Free Trial

Verici Dx's Total Receivables for the quarter that ended in Jun. 2023 was $0.14 Mil.


Verici Dx Total Receivables Historical Data

The historical data trend for Verici Dx's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Total Receivables
0.12 0.25 0.18

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Total Receivables 0.22 0.25 0.19 0.18 0.14

Verici Dx Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Verici Dx Total Receivables Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines